

Patient: James A. Doe

Case No: P11-03559



DOB/Gender: xx/xx/xxxx (66 yrs) – Male

MRN/ID: 234567

Collected: xx/xx/xx

Received: xx/xx/xx

Reported: xx/xx/xx

Provider: John Doe, M.D.

Account: Pathology Associates

Phone: 800-123-4567 Fax: 800-123-4444

Alert Status: Routine

Report Status: Final

Report Category: **Malignant**

Clinical information: ICD-9 162.9. Lung adenocarcinoma.

Specimens received: 1 Paraffin block and 1 H&E-stained slide



Yale SCHOOL OF MEDICINE Professional Services Provided By

**DIAGNOSIS:**


Embedded tissue (#S11-0265), lung biopsy: **Metastatic carcinoma in lung with clear cell features. Immunohistochemical profile consistent with a metastatic renal cell carcinoma. See interpretation.**

**COMMENT:**

Clinicopathologic correlation is recommended.

**MICROSCOPIC DESCRIPTION:**

Sections of lung tissue show nodules of an epithelioid-type proliferation, growing in ill-defined nests, separated by blood vessels in areas showing clear cytoplasm with irregular oval-shaped nuclei, characterized at the immunohistochemical level by expression of low-molecular weight Cytokeratin CAM 5.2 with coexpression of EMA. In addition, tumor cells show strong expression of Vimentin and coexpress renal-associated marker PNRA, confirming metastatic renal carcinoma. S100 protein shows only focal weak positivity and CD1a is unreactive, ruling out eosinophilic granuloma. There is no immunoreactivity with TTF-1 and Cytokeratin 7, ruling out a primary carcinoma of lung.




H&E

Electronically Signed By: S. David Hudnall, MD, FCAP

**RESULT:**

Stain	Result
CAM 5.2	Positive
CD1A	Negative
S100	Positive - Focal/Weak
TT 8	Negative
Vimentin	Positive
EMA	Positive
CK7	Negative



IHC

**GROSS DESCRIPTION:**

Received on 06/12/2011 from Pathology Associates are 1 H&E-stained and 1 paraffin block labeled S11-07265-A1.

Disclaimer: The adequacy of staining is verified by the appropriate positive and negative controls. The reagents used for these assays are analyte specific reagents (ASR). Their performance characteristics have been validated by Precipio Diagnostics, LLC, New Haven, CT. They have not been reviewed by the FDA. The FDA has deemed that such approval is unwarranted. These assays are for clinical use and should not be viewed as experimental or "research use only".

**END OF REPORT**